文献速递核素与放射性配体治疗

面向177Lu-PSMA-617治疗的单时间点图像剂量测定

Toward Single-Time-Point Image-Based Dosimetry of 177Lu-PSMA-617 Therapy.
PubMed 文献 · J Nucl Med · 2023-01-19

本研究纳入20例转移性去势抵抗性前列腺癌患者,比较单时间点(STP)与多时间点(MTP)图像剂量测定在177Lu-PSMA-617治疗中时间积分活度(TIA)的差异。结果显示,采用Hänscheid公式或基于第一周期有效半衰期的先验信息法,在注射后48或72小时单次SPECT/CT扫描,与MTP相比TIA百分比差异小于±20%。作者认为STP剂量测定可行,可能促进剂量测定在常规临床工作流程中的实施。

要点

  • 在注射后48小时使用Hänscheid公式对肾脏进行STP剂量测定,与MTP相比TIA百分比差异为-1.3%±5.6%。
  • 在注射后48小时使用先验信息法对56个病灶进行STP剂量测定,与MTP相比TIA平均百分比差异最小,为0.4%±14.9%。
  • 使用单次SPECT/CT在注射后48或72小时进行STP剂量测定可行,与MTP相比百分比差异小于±20%。

核心结论

  • 使用单次SPECT/CT在注射后48或72小时进行177Lu-PSMA-617治疗的STP剂量测定可行,与MTP相比百分比差异小于±20%。
  • Hänscheid公式和先验信息法两种STP方法的有效性均已得到证明。
  • 作者认为该发现可增加剂量测定的采用并促进其在常规临床RPT工作流程中的实施,最终基于固定治疗活度发现剂量-效应关系,未来可能实现基于吸收剂量的RPT活度个体化。

研究设计与样本

  • 本研究纳入20例转移性去势抵抗性前列腺癌患者,这些患者在第一和第二周期177Lu-PSMA-617治疗中具有多时间点定量177Lu-SPECT成像数据(约注射后24、48和72小时)。
  • 对肾脏和病灶拟合时间-活度曲线以推导有效半衰期并获得参考TIA。
  • STP方法包括Hänscheid公式(STPH)和利用第一治疗周期有效半衰期的先验信息法(STPprior),所有时间点均被考虑用于STP方法。
  • 在第二治疗周期比较STP与MTP之间TIA的百分比差异。

主要发现

  • 在注射后48小时使用STPH对肾脏进行STP剂量测定,与MTP相比TIA百分比差异为-1.3%±5.6%;使用STPprior的百分比差异为4.6%±6.2%。
  • 对于56个研究的单个病灶,在注射后48小时使用STPprior发现最小的平均百分比差异,仅为0.4%±14.9%;而注射后72小时使用STPH的最小百分比差异为-1.9%±14.8%。

临床怎么用

  • 作者认为该发现可增加剂量测定的采用并促进其在常规临床RPT工作流程中的实施。
  • 作者认为这样做最终将基于固定治疗活度发现剂量-效应关系,未来可能实现基于吸收剂量的RPT活度个体化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radiopharmaceutical therapies (RPTs) with 177Lu-prostate-specific membrane antigen (PSMA) ligands have demonstrated promising results for the treatment of metastatic castration-resistant prostate cancer. The lack of absorbed-dose-effect relationships currently prevents patient-specific activity personalization. To ease the implementation of dosimetry in the routine clinical workflow for RPT, simplified methods such as single-time-point (STP) instead of multiple-time-point (MTP) imaging protocols are required. This work aimed at assessing differences in the time-integrated activity (TIA) of STP versus MTP image-based dosimetry for 177Lu-PSMA-617 therapy. Methods: Twenty metastatic castration-resistant prostate cancer patients with MTP quantitative 177Lu-SPECT imaging data (∼24, 48, and 72 h post injection (p.i.)) available on first and second 177Lu-PSMA-617 therapy cycles were included in this study. Time-activity curves were fitted for kidneys and lesions to derive effective half-lives and yield a reference TIA. STP approaches involved the formula by Hänscheid (STPH) and a prior-information method (STPprior) that uses the effective half-lives from the first therapy cycle. All time points were considered for the STP approaches. Percentage differences (PDs) in TIA between STP and MTP were compared for the second therapy cycle. Results: Using STPH at 48 h p.i. for kidneys showed a -1.3% ± 5.6% PD from MTP, whereas STPprior showed a PD of 4.6% ± 6.2%. The smallest average PDs for the 56 investigated individual lesions were found using STPprior at 48 h p.i., at only 0.4% ± 14.9%, whereas STPH at 72 h p.i. had a smallest PD of -1.9% ± 14.8%. Conclusion: STP dosimetry for 177Lu-PSMA-617 therapy using a single SPECT/CT scan at 48 or 72 h p.i. is feasible, with a PD of less than ±20% compared with MTP. The validity of both STPH and STPprior has been demonstrated. We believe this finding can increase the adoption of dosimetry and facilitate implementation in routine clinical RPT workflows. Doing so will ultimately enable the finding of dose-effect relationships based on fixed therapy activities that may, in future, allow for absorbed-dose-based RPT activity personalization.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Brosch-Lenz J, Delker A, Völter F, et al. Toward Single-Time-Point Image-Based Dosimetry of 177Lu-PSMA-617 Therapy. J Nucl Med. 2023. PMID: 36657980. doi:10.2967/jnumed.122.264594

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。